Maternal-Neonatal COVID-19 General Guideline

Updated October 22, 2020
Acknowledgments

The Provincial Council for Maternal and Child Health (PCMCH) would like to thank the PCMCH Maternal-Neonatal COVID-19 Task Force, PCMCH Maternal-Newborn Committee, and other additional stakeholders for their support in the development of the *Maternal-Neonatal COVID-19 General Guideline*.

For consideration:

In this guiding document, we are referring to the pregnant individual as “woman” and/or “mother” to reflect their capacity of having a birthing/perinatal experience. Surrogates, gestational carriers, transgender males and persons who do not identify as cisgendered women may also share these experiences, and may also benefit from the recommendations below.

This document and outlined key practice principles are meant to be clinically applicable for a wide range of populations. Ontario is home to diverse pregnant and postpartum populations; inclusive of age, gender identity, race, ethnicity or culture, ability, means of conception or genetic relation, and other factors such as geographical location. These factors can greatly influence a person’s unique needs, and expectations around care management during pregnancy and postpartum. When appropriate, health care providers (HCP) should consult with specialized organizations dedicated to support of specific populations for assistance in appropriately tailoring these recommendations to the patient under their care.
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barrett, Jon (Co-Chair)</td>
<td>Chief, Maternal Fetal Medicine Program</td>
<td>Sunnybrook Health Sciences</td>
</tr>
<tr>
<td></td>
<td>Vice-Chair, Quality Improvement &amp; Patient Safety, Department of Obstetrics and Gynaecology</td>
<td>University of Toronto</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Southern Ontario Obstetrical Network</td>
</tr>
<tr>
<td>Walker, Mark (Co-Chair)</td>
<td>Chief, Department of Obstetrics, Gynecology and Newborn Care</td>
<td>The Ottawa Hospital</td>
</tr>
<tr>
<td></td>
<td>Scientific Director, Medical Lead</td>
<td>Better Outcomes Registry Network (BORN) Ontario</td>
</tr>
<tr>
<td>Prakashkumar, Shah</td>
<td>Chief, Department of Pediatrics, Senior Clinician Scientist, Lunenfeld-Tanenbaum Research Institute Professor, Departments of Paediatrics and Institute of HPME Chair in Reproductive and Child Health Services and Policy Research Director</td>
<td>Mount Sinai Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of Toronto</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Canadian Institute of Health Research Applied Research</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Canadian Neonatal Network</td>
</tr>
<tr>
<td>Katherine, Wendy</td>
<td>Executive Director, Interim Executive Director</td>
<td>Best Start: Health Nexus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Southern Central Maternal Child Regional Network</td>
</tr>
<tr>
<td>Sprague, Ann</td>
<td>Project Advisor</td>
<td>BORN Ontario</td>
</tr>
<tr>
<td>Williams, Connie</td>
<td>Neonatal Medicine and Ethics</td>
<td>McMaster Children's Hospital</td>
</tr>
<tr>
<td>Ejiwunmi, Aderemi (Remi)</td>
<td>Head of Midwifery, Partner</td>
<td>Trillium Health Partners, Mississauga Partner Midwives of Mississauga</td>
</tr>
<tr>
<td>Yang, Homer</td>
<td>Chief, Department of Anesthesia &amp; Perioperative Medicine Anesthesia/ ICU Professor &amp; Chair, Department of Anesthesia &amp; Perioperative Medicine Schulich School of Medicine</td>
<td>London Health Sciences Centre</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Western University</td>
</tr>
<tr>
<td>Money, Deborah</td>
<td>Professor Obstetrics &amp; Gynecology, Executive Vice-Dean, Faculty of Medicine Infectious Diseases Committee</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Society of Obstetrics &amp; Gynecology of Canada (SOGC)</td>
</tr>
<tr>
<td>Le Saux, Nicole</td>
<td>Infectious Disease Consultant Co-Chair, Infectious Diseases and Immunization Committee</td>
<td>Children’s Hospital of Eastern Ontario</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Canadian Paediatric Society</td>
</tr>
<tr>
<td>Miller, Katherine Judith (Kate)</td>
<td>Lead Physician, Family Practice Obstetrics and Well Newborn Care</td>
<td>Guelph General Hospital</td>
</tr>
<tr>
<td>Gubbay, Jonathon</td>
<td>Medical Microbiologist</td>
<td>Public Health Ontario</td>
</tr>
<tr>
<td>Falzon, Kelly</td>
<td>Director, Women and Newborn Health</td>
<td>McMaster Children’s Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hamilton Health Sciences Centre</td>
</tr>
<tr>
<td>Harrold, JoAnn</td>
<td>Neonatologist</td>
<td>Children’s Hospital of Eastern Ontario and The Ottawa Hospital</td>
</tr>
<tr>
<td>Hubbert, Jackie</td>
<td>Interim Executive Director</td>
<td>Provincial Council for Maternal and Child Health</td>
</tr>
<tr>
<td>Jia, Aileen</td>
<td>Program Coordinator</td>
<td>Provincial Council for Maternal and Child Health</td>
</tr>
<tr>
<td>Webel-Edgar, Lori</td>
<td>Senior Program Manager</td>
<td>Provincial Council for Maternal and Child Health</td>
</tr>
<tr>
<td>Zahreddine, Laura</td>
<td>Senior Program Manager</td>
<td>Provincial Council for Maternal and Child Health</td>
</tr>
</tbody>
</table>

This disclaimer informs readers that the views, thoughts, and opinions expressed in the text belong solely to the authors, and not necessarily to the authors' employer, organization, committee or other group or individual.
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Organization</th>
<th>Representation</th>
<th>LHIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seaward, Gareth</td>
<td>Maternal Fetal Medicine Specialist, Ontario Fetal Centre</td>
<td>Sinai Health System</td>
<td>Committee Co-Chair</td>
<td>7</td>
</tr>
<tr>
<td>(Co-Chair)</td>
<td>Associate Medical Director</td>
<td>CritiCall Ontario</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taggar, Ru</td>
<td>Executive Vice President, Chief Nursing and Health Professions Executive VP</td>
<td>Sunnybrook Health Sciences Centre</td>
<td>Committee Co-Chair</td>
<td>7</td>
</tr>
<tr>
<td>(Co-Chair)</td>
<td>Quality/Patient Safety</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blais, Ellen</td>
<td>Director, Indigenous Midwifery</td>
<td>Association of Ontario Midwives</td>
<td>Indigenous Midwifery</td>
<td>7</td>
</tr>
<tr>
<td>Brandeis, Elizabeth</td>
<td>President</td>
<td>Association of Ontario Midwives</td>
<td>Midwifery</td>
<td>7</td>
</tr>
<tr>
<td>Carew, Wendy</td>
<td>Population Health Lead, North East LHIN</td>
<td>LHIN 13 Maternal-Child Health Care Network</td>
<td>Regional Networks North East</td>
<td>13</td>
</tr>
<tr>
<td>Edwards, Crystal</td>
<td>Director of Women and Children's Program</td>
<td>Thunder Bay Regional Health Sciences Centre</td>
<td>Regional Networks North West</td>
<td>14</td>
</tr>
<tr>
<td>Harrold, JoAnn</td>
<td>Neonatologist Division Chief of Neonatology</td>
<td>Children’s Hospital of Eastern Ontario</td>
<td>Neonatology</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>Division Head of Newborn Care</td>
<td>The Ottawa Hospital</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Newborn Lead</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Katherine, Wendy</td>
<td>Interim Executive Director of the South Central Regional Network</td>
<td>Southern Ontario Regional Maternal Child Network</td>
<td>Regional Networks South Central</td>
<td>3-9 &amp; 12</td>
</tr>
<tr>
<td>Maxwell, Cynthia</td>
<td>Maternal-Fetal Medicine Specialist; Division Head, Maternal Fetal Medicine</td>
<td>Sinai Health System</td>
<td>Maternal-Fetal Medicine</td>
<td>7</td>
</tr>
<tr>
<td>McArthur, Leanne</td>
<td>Executive Director</td>
<td>Southwestern Ontario Maternal Newborn, Child, Youth Network</td>
<td>Regional Networks South West</td>
<td>1 &amp; 2</td>
</tr>
<tr>
<td>Miller, Kate</td>
<td>Lead Physician, Family Practice Obstetrics and Well Newborn Care</td>
<td>Guelph General Hospital</td>
<td>Family Practice</td>
<td>3</td>
</tr>
<tr>
<td>Rose, Darlene</td>
<td>Regional Director</td>
<td>Champlain Maternal Newborn Regional Program</td>
<td>Regional Networks South East</td>
<td>10 &amp; 11</td>
</tr>
<tr>
<td>Cossar, Kathryn</td>
<td>Obstetrician/Gynaecologist</td>
<td>Timmins and District Hospital</td>
<td>Obstetrics</td>
<td>13</td>
</tr>
</tbody>
</table>

**Ex Officio**

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Organization</th>
<th>Representation</th>
<th>LHIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bisnaire, Lise</td>
<td>Executive Director</td>
<td>Better Outcomes Registry Network (BORN) Ontario</td>
<td>BORN Ontario</td>
<td>Provincial</td>
</tr>
<tr>
<td>Barrett, Jon</td>
<td>Vice-Chair, Quality Improvement &amp; Patient Safety, Department of Obstetrics and Gynaecology</td>
<td>Sunnybrook Health Sciences University of Toronto</td>
<td>Pre-Term Birth Priority Project</td>
<td>Provincial</td>
</tr>
<tr>
<td>Deland, Marion</td>
<td>Manager</td>
<td>Critical Care Services Ontario</td>
<td>Critical Care Services Ontario</td>
<td>Provincial</td>
</tr>
<tr>
<td>Dempsey, Joanne</td>
<td>Senior Improvement Advisor</td>
<td>CritiCall Ontario</td>
<td>CritiCall Ontario</td>
<td>Provincial</td>
</tr>
<tr>
<td>Gratton, Rob</td>
<td>Maternal Fetal Medicine Consultant, Dept. of Obstetrics and Gynecology</td>
<td>London Health Sciences Centre</td>
<td>Safer Birth Priority Project Lead</td>
<td>Provincial</td>
</tr>
<tr>
<td>Taylor, Kristen</td>
<td>Director</td>
<td>Provincial Programs Branch</td>
<td>Ministry of Health</td>
<td>Provincial</td>
</tr>
<tr>
<td>Walker, Mark</td>
<td>Chief, Department of Obstetrics, Gynecology and Newborn Care</td>
<td>The Ottawa Hospital</td>
<td>Safer Birth Priority Project Lead</td>
<td>Provincial</td>
</tr>
<tr>
<td></td>
<td>Scientific Director</td>
<td>Better Outcomes Registry Network (BORN) Ontario</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medical Lead</td>
<td>Obstetrics and Gynecology, Champlain Maternal Newborn Regional Program</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Contents

Acknowledgments .................................................................................................................................................. 2

About the Provincial Council for Maternal and Child Health .......................................................................... 7

Vision ................................................................................................................................................................. 7

Mission .............................................................................................................................................................. 7

Maternal-Neonatal COVID-19 General Guideline .............................................................................................. 8

Revision History .................................................................................................................................................. 8

Summary of Recommendations .......................................................................................................................... 8

A. Use of Personal Protective Equipment (PPE) by Providers and Patients during Labour & Delivery 8

   Use of Droplet-Contact PPE .......................................................................................................................... 8

   Use of Airborne PPE/N95 Respirator ............................................................................................................ 9

B. Support People for Pregnant Patients during a Labour & Delivery Admission ........................................... 9

C. Care of Babies born to Suspected and Confirmed COVID-19 Mothers ..................................................... 9

D. Infant Testing .................................................................................................................................................. 9

E. Care and Testing of Babies in NICU/SCN ..................................................................................................... 9

F. Monitoring/Surveillance Recommendations .................................................................................................. 10

Introduction .......................................................................................................................................................... 11

   Task Force General Values and Principles .................................................................................................... 11

      A. Underlying Values ....................................................................................................................................... 11

      B. Goals & Principles ..................................................................................................................................... 12

Use of Personal Protective Equipment (PPE) by Providers and Patients during Labour & Delivery .......... 12

   Use of Droplet-Contact PPE .......................................................................................................................... 12

   Use of Airborne PPE/N95 Respirators ............................................................................................................ 13

   Figure 1: PPE Requirements for all Obstetrical Deliveries ......................................................................... 14

Support People for Pregnant Patients during a Labour & Delivery Admission ............................................ 14

Intrapartum Care Considerations for Suspected/Confirmed COVID-19 Patients .......................................... 16

Care of Babies born to Asymptomatic or Non-Suspect Mothers .................................................................... 17

Care of Babies born to Suspected and Confirmed COVID-19 Mothers ............................................................ 17

Mother-Baby Dyad Care for Suspected/Confirmed COVID-19 Mothers ......................................................... 18

Infant Testing .................................................................................................................................................... 19

Babies Requiring Transfer to a Higher Level of Care of NICU/Special Care Nursery (SCN) ......................... 20
About the Provincial Council for Maternal and Child Health

The mandate of the Provincial Council for Maternal and Child Health (PCMCH) is to provide evidence-based and strategic leadership on maternal, newborn, child and youth health care services in Ontario. This includes addressing and supporting provincial coordination of planning, innovation, monitoring and knowledge management for maternal, newborn, child and youth health care services and/or standards across both community and hospital settings. The overall goal of PCMCH is to support the development of a system of care that provides timely, equitable, accessible, high quality, evidence-based, family-centred care in an efficient and effective manner.

Vision
Healthy pregnancies, babies, children and families for lifelong health in Ontario.

Mission

- **Be the provincial forum** in which families, caregivers, clinical and administrative leaders in maternal, child and youth health can identify patterns, issues of importance and improvement opportunities in health and health care delivery.

- **Enhance the delivery and experience of maternal, child and youth health care services** by engaging individuals, families and their care providers in building provincial consensus regarding standards of care, leading practices and priorities for system improvement, and monitoring of the performance of Ontario’s maternal and child health care system.

- **Be a trusted leader and voice** to Ontario’s maternal, child and youth health care providers, planners and stewards in order to improve the care experience and overall health care system performance.

- **Facilitate knowledge to action** that will support individuals, caregivers, health care providers and planners in improving the health and wellbeing of children, youth, and families.
Maternal-Neonatal COVID-19 General Guideline

Revision History

<table>
<thead>
<tr>
<th>Topic</th>
<th>Previous Content</th>
<th>Revised Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal Fever During Labour</td>
<td>COVID-19 should be suspected in all women manifesting a persistent (on two occasions, 30 minutes apart) fever of 37.8°C or greater in labour.</td>
<td>COVID-19 should be suspected in all pregnant women manifesting with an unexplained, persistent (on two occasions, 30 minutes apart) fever (&gt;37.8) and testing for SARS-CoV2 should be performed. While testing should be considered for any febrile women in labour, if community prevalence remains low and an alternate cause of fever is clear it is reasonable not to test.</td>
</tr>
<tr>
<td>Use of Nitrous Oxide</td>
<td>In light of uncertain evidence and logical deductions based on its mechanical function, there is concern that the use of patient administered nitrous oxide use may increase viral load in the care environment. Therefore precautionary principles suggest not to use it during labour and delivery.</td>
<td>There is a lack of comprehensive and definitive evidence on the risk of nitrous oxide use and COVID-19. Therefore precautionary principles suggest that a biomedical filter should be applied along with adequate sanitization of equipment if nitrous oxide is used during labour and delivery.</td>
</tr>
</tbody>
</table>

April 30th, 2020 – Original Release

Summary of Recommendations

A. Use of Personal Protective Equipment (PPE) by Providers and Patients during Labour & Delivery

Use of Droplet-Contact PPE

1. A point of care risks assessment should be done by regulated health professionals (RHP) for risk of droplet and contact transmission during labour, delivery, and newborn care. Suitable precautions may include: gloves, gown, a surgical/procedure mask, and eye protection (goggles or face shield). Droplet-contact precautions is recommended for all health care providers at all births in Ontario.

2. Pregnant patients who screen positive for signs/symptoms of COVID-19 should be treated as suspected for COVID-19, should be given a surgical/procedure mask for all stages of labour (if tolerated) and be advised to perform hand hygiene.
Use of Airborne PPE/N95 Respirator

3. Only essential OR staff should be in the room for administration of general anesthesia for a caesarian section, such staff should follow Airborne precautions (including appropriately fitted N95 mask). Once intubation is complete, other regulated health professionals (RHP) may enter the room and use Droplet/Contact precautions.

4. All staff present in the operating room for caesarean section under regional anesthesia should use Droplet/Contact precautions. In the event that regional anesthesia is not sufficient and the procedure needs to be converted to general anesthesia, only necessary RHPs should be in the room for intubation and Contact/Droplet and Airborne precautions should be used. Once intubation is complete and ventilation initiated, other RHPs may enter the room and use Droplet/Contact precautions.

B. Support People for Pregnant Patients during a Labour & Delivery Admission

5. A single support person who should remain unchanged during labour and birth and was screened negative for symptoms of COVID-19, be allowed to accompany the birthing mother as long as the institution has the following:
   i. Sufficient PPE for support person;
   ii. Adequate spacing and care environment in which support people can be appropriately physically distanced from other patients and support people; and
   iii. The ability to ensure that the support person remains compliant with physical distancing and infection control instructions.

C. Care of Babies born to Suspected and Confirmed COVID-19 Mothers

6. Given the low risk of vertical transmission and the low risk of aerosol exposure from neonatal resuscitation, Droplet/Contact precautions are suitable for the initial resuscitation of newborns, even those born to suspected or confirmed COVID-19 mothers.

7. This group recommends early discharge of well babies, after proper risk assessment has occurred.

D. Infant Testing

8. Infants born to mothers with confirmed COVID-19 at the time of birth should be tested for COVID-19 within 24 hours of delivery, regardless of symptoms.

9. If maternal testing is pending at the time of mother-baby dyad discharge then follow-up must be ensured such that if maternal testing is positive the baby is tested in a timely manner. If bringing the baby back for testing is impractical, the baby should be tested prior to discharge.

E. Care and Testing of Babies in NICU/SCN

10. RHPs providing care for babies requiring ongoing, potentially aerosolizing respiratory support in the NICU or SCN should use Airborne and Droplet/Contact precautions.

11. If any visitor to NICU or RHP is determined to be a suspected or confirmed COVID case, the baby becomes a possible contact and should be isolated with appropriate additional precautions instituted. Hospital IPAC should be notified to institute proper follow-up. Any infant who is a post-
natal contact of a confirmed COVID positive caregiver or RHP should remain isolated with appropriate additional precautions for 14 days according to MOH or local guidelines.

12. Infants born to COVID-19 positive mothers should be tested within the first 24 hours of life and, if the initial test is negative, again at 48 hours of life, regardless of symptoms. Infants should be maintained on Droplet/Contact precautions with or without Airborne precautions as appropriate until results are reported.
   i. Infants who have a 24 or 48 hour COVID test positive should be discussed with a pediatric infectious disease specialist.
   ii. Infants who have a negative test at 48 hours should be discussed with local IPAC to determine appropriate ongoing care measures.

F. Monitoring/Surveillance Recommendations

13. The task force feels it imperative that prospective surveillance of the mother-baby dyad be performed postpartum until 2 weeks to ensure the safety of this recommendation.
Introduction

The COVID-19 pandemic has resulted in multiple practice guidelines from international, national, regional and local authorities in an attempt to advise health practitioners and patients on safe practice related to childbirth and newborn care. These guidelines are often written by various specialty subgroups resulting in conflicting messages to healthcare practitioners and the public. Furthermore, many guidelines are being adapted from non-Canadian data leading to uncertainty in the appropriateness of these guidelines to Canadian practice. As a result, there are wide differences in maternal and newborn care practices across Ontario. This variation in practice guidelines has led and will continue to lead to confusion for pregnant individuals and their support system, and are stressful for families and healthcare providers alike. Additionally, there is concern that individual institutional or provider interpretation of the guidelines will result in inappropriate use of limited provincial resources such as personal protective equipment (PPE).

The Maternal-Neonatal COVID-19 Task Force was charged by the Ontario Ministry of Health with addressing two main areas for consideration. The first is the use of PPE among healthcare providers and patients during the pandemic, and the second is addressing how visitors may support the pregnant patient at hospitals during this pandemic response with the goal of equitable and safe care across Ontario. This document has also addressed additional areas for concern that are being experienced by providers across the regions including recommendations for intrapartum care, breast-feeding, separation of the mother & baby dyad, and neonatal testing for COVID-19. These recommendations were made after considerable deliberation by a task force representing a wide range of clinical expertise including (but not limited to) microbiology and infectious disease (see membership list included).

The task force considered information from existing guidelines and references to formulate these recommendations. For the most part, this document aligns with Canadian guidelines and only differs where Ontario practice specific data was needed. The task force made recommendations that represent a general agreement from its members. In the rare event where there was not unanimous agreement, recommendations were based on majority agreement. Where recommendations from guidelines diverged, the task force applied the following principles and values:

Task Force General Values and Principles

A. Underlying Values

1. **Beneficence**: Promoting safe and effective care within resource constraints and limitations of current evidence.

2. **Equity**: Promoting just/fair distribution of benefit and burdens in time of pandemic.

3. **Reciprocity**: Minimizing exposures for all, including health care professionals (HCPs) and patients, based on risk and institutional prevalence.

4. **Solidarity**: Building, preserving, and strengthening inter-professional and inter-institutional collaboration (a responsibility of HCPs, institutional leadership, and the Ministry).

5. **Trust**: Foster and maintain the public’s trust and HCP’s trust in each other, in leadership, and in their institutions.
6. **Utility**: Balancing the values above and the principles below to maximize the greatest possible good for the greatest number of individuals.

**B. Goals & Principles**

1. To promote public health aims of reducing transmission and preserving PPE supplies.
2. To conserve continuity / consistency of care as best as possible for patients / families.
3. To support health/resilience in our workforce and preserve future staffing for patient care.
4. To perform ongoing surveillance and evaluation of new evidence to inform guidelines.

This task force was asked to provide the province with the recommendations that would standardize practice across the province in an attempt to reduce the variations among providers and across all birth settings in the province of Ontario. The recommendations that follow are made to reflect the current pandemic and integrate best scientific evidence in the context of a potential scarcity of resources.

**Use of Personal Protective Equipment (PPE) by Providers and Patients during Labour & Delivery**

**Use of Droplet-Contact PPE**

It is clear that the COVID-19 virus spreads largely by droplets and therefore proper use of droplet-contact precautions PPE should be implemented to prevent spread among healthcare providers. We support the recommendation that patients with suspected or confirmed COVID-19 infection should only be cared for by providers who have adequate droplet-contact infection prevention unless involved in Aerosol Generating Medical Procedures (AGMPs) where airborne precautions are recommended.

A point of care risks assessment should be done by regulated health professional (RHP) for risk of droplet and contact transmission during labour, delivery, and newborn care. Suitable precautions may include: gloves, gown, a surgical/procedure mask, and eye protection (goggles or face shield). This panel therefore recommends droplet-contact precautions for all health care providers at all births in Ontario.

A recent case series demonstrated that 13.5% of pregnant patients without any COVID-19 associated symptoms at initial presentation, were later identified as COVID-19 positive after either developing symptoms or following the implementation of universal testing (Desmond Sutton, 2020) (Chen , Guo , Wang , & et al. , 2020). Additionally, coughing individuals with corona virus produced droplets, which were effectively shielded using surgical masks (Nancy H. L. Leung, 2020) (Public Health Ontario, 2020).

The care of all babies born to mothers who are not suspected to have COVID-19 will continue to follow universal precautions in accordance with Ministry of Health guidance (Public Health Ontario, 2020).

Therefore this panel recommends that all pregnant patients who screen positive for signs/symptoms of COVID-19 should be treated as suspected for COVID-19, should be given a surgical/procedure mask for all stages of labour (if tolerated) and be advised to perform hand hygiene.
Use of Airborne PPE/N95 Respirators

The MOH has recommended that N95 Respirators be limited to use only in the presence of AGMPs (Public Health Ontario, 2020). This best practice continues to apply within the COVID-19 environment. In obstetrical care environments, this recommendation chiefly addresses caesarean sections under general anesthetic (GA) which represents between 3 to 5% of all caesarean sections in Ontario.

Only essential OR staff should be in the room for administration of general anesthesia for a caesarean section, such staff should follow Airborne precautions (including appropriately fitted N95 mask). Once intubation is complete, other RHPs may enter the room and use Droplet/Contact precautions.

In order to conserve PPE, all acute care settings should define the minimum team required to provide a safe caesarean section and aim to eliminate unnecessary health care providers in the OR.

In some cases, a caesarean section may begin under regional anesthesia and then need to convert to general anesthetic. It is theoretically possible for the anesthesia to be induced by an anesthetic team wearing an N95 mask and then for the rest of the health care team to wait for the operating room atmosphere to clear of potentially aerosolized virus before commencing the surgery. However, this panel is of the opinion that this will lead to an unnecessary delay in what is likely an emergency caesarean section and unnecessary prolonged exposure of the fetus to the anesthetic.

This panel recommends that all staff present in the operating room for caesarean section under regional anesthesia should use Droplet/Contact precautions. In the event that regional anesthesia is not sufficient and the procedure needs to be converted to general anesthesia, only necessary RHPs should be in the room for intubation and Contact/Droplet and Airborne precautions should be used. Once intubation is complete and ventilation initiated, other RHPs may enter the room and use Droplet/Contact precautions.
Support People for Pregnant Patients during a Labour & Delivery Admission

A significant area of contention for providers is the issue of sites allowing a support person or people to accompany the labouring woman and immediately thereafter. While the same basic principles apply to all birth environments, this taskforce recognizes that local factors will result in some variation from institution to institution and region to region. It is also recognized that variations in policies cause significant confusion and concern for pregnant women and the public and urge institutions to clearly communicate their policies along with the rationale behind the decisions made.

In determining whether to enable a support person to attend the birth and participate in the postpartum period, obstetrical care environments (or providers) need to balance the known risks of SARS-CoV-2 transmission with the benefit of having a support person present during labour. Given the high prevalence of asymptomatic disease, these risks are present for all admissions but are more clear and likely greater for those suspected and/or COVID-19 positive. In creating this policy, institutions should consider the following:

- Support person may require PPE during a time of significant PPE rationalization
- Health care environments should screen the visitor prior to entry to the facility. Suspect/Confirmed COVID-19 visitors are typically denied entry. Allowing a support person with
suspected or confirmed COVID-19 to accompany a pregnant individual will increase the risk of virus transmission to health care providers and threaten maintaining a healthy provider workforce for the duration of the pandemic.

- An asymptomatic visitor also poses a risk to both care providers and other patients in the care environment.
- Exposing a well support person to potential viral transmissions may not be ethical or appropriate when the severity of the disease for the individual is unpredictable or unknown.
- Healthcare provider anxiety may increase due to real or perceived exposure to virus from infected, exposed and/or asymptomatic individuals
- Support person may require resources and logistical considerations outside of normal care practices

These considerations must be balanced against the following risks of removing support:

- Birth is an emotional event and can often be anxiety provoking and even traumatic. The presence of support can mitigate these effects.
- Continuous support in labour can reduce some complications. Support in the postpartum period increases desirable outcomes such as successful breastfeeding and readiness for early discharge (Bohren, Hofmeyr, Sakala, Fukuzawa, & Cuthbert, 2017).
- An extra staff person may be needed for each labour/birth to help with tasks normally taken by the support person. This may compound difficulties due to reduced staffing availability and increased workload created by infection control measures

Considering all the above, this task forces recommends a single support person who shall remain unchanged during labour and birth and was screened negative for symptoms of COVID-19, be allowed to accompany the birthing mother as long as the institution has the following:

- Sufficient PPE for support person;
- Adequate spacing and care environment in which support people can be appropriately physically distanced from other patients and support people; and
- The ability to ensure that the support person remains compliant with physical distancing and infection control instructions.

Additional factors to consider:

- Movement through and between care environments by the support person should be minimized.
- In and Out privileges should be discouraged and supports may be required to remain in the patient room at all times.
- Differing policies may apply to women who are suspected or confirmed COVID-19 than to asymptomatic women.
• Differing policies may apply to differing obstetrical and newborn care environments (eg triage, labour and delivery, postpartum).
• If the support person is to accompany a pregnant patient, the same recommendations on PPE precautions must taken.
• Where in-person support is not possible, virtual and/or alternative options for support should be provided. When distance support is given, practical physical support should be provided.
• Policies should be flexible enough to address exceptional considerations (e.g. need for language interpretation, critically ill women) as well as to encompass the diversity of families we care for (e.g. adoptive and surrogacy families, persons with disabilities).

**Intrapartum Care Considerations for Suspected/Confirmed COVID-19 Patients**

• Regardless of whether the woman is suspected or confirmed COVID-19, her place of birth will continue to be informed by obstetrical factors and her birth place preferences. Women should deliver in a care environment that can meet both her needs and the needs of the newborn while receiving care for COVID-19.
• Movement within and between facilities should be minimized. COVID-19 alone should not be an indication for transfer but may be a consideration.
• Timing of delivery should be determined by obstetrical indications. Suspected or confirmed COVID-19 status alone is not a sufficient indication for induction or caesarean delivery.
• Delivery for suspected or confirmed COVID-19 pregnant women may be expedited for fetal reasons, or if it is felt that delivery will help maternal resuscitation. If delivery is required, maternal stabilization should be the priority.
• Infection control precautions and PPE recommendations should be followed as listed above.
• COVID-19 should be suspected in all pregnant women manifesting with an unexplained, persistent (on two occasions, 30 minutes apart) fever (>37.8) and testing for SARS-CoV2 should be performed. While testing should be considered for any febrile women in labour, if community prevalence remains low and an alternate cause of fever is clear it is reasonable not to test.
• There is a lack of comprehensive and definitive evidence on the risk of nitrous oxide use and COVID-19. Therefore precautionary principles suggest that a biomedical filter should be applied along with adequate sanitization of equipment if nitrous oxide is used during labour and delivery.
• The use of water immersion (for pain relief or birth) should be avoided. If showering is used for pain relief, care providers should be protected from exposure from spray.
• The use of all other analgesia options (e.g. epidurals, opioids) is not changed by COVID-19 positive status.
• Fetal health surveillance should continue as routinely practiced, in accordance with obstetrical indications.
• Amniotomy and fetal scalp clips may be used.
• Delayed cord clamping is recommended for preterm infants and there is no reason not to do this for term babies as there is no supporting evidence to say otherwise. However, this practice is not recommended for babies born by caesarean section under general anesthesia (see below).
• Skin-to-skin can be performed by the mother, provided skin cleansing occurs first.

Care of Babies born to Asymptomatic or Non-Suspect Mothers
Providers are asked to continue to wear a mask as routinely practiced, following your local institution’s current guidelines. This is aligned with the above recommendations and in accordance with Ontario Ministry of Health recommendations.

Care of Babies born to Suspected and Confirmed COVID-19 Mothers
It is reassuring to note in the short term there have only been a few reported cases of infected infants. However, post-natal transmission is a potential risk of unknown scale. While there are no documented deaths of infants from COVID-19, there is limited evidence to suggest babies under one year of age may experience increased severity of disease from COVID-19 infection than older children. As a result, all efforts should be made to prevent postnatal transmission both in hospital and in the community.

Currently, in the literature there is no convincing evidence of in-utero transmission of COVID-19 to the fetus (Chen, Guo, Wang, & et al., 2020). As a result, this information may not be representative of vaginal births and it is theoretically possible that the child born vaginally, as is anticipated more commonly in Ontario, may have a risk of SARS-CoV-2 colonization. However, there have been several cohorts reported with no virus detection in vaginal secretions in COVID-19 positive women. In addition, the neonatal respiratory tract is narrow (largest endotracheal tube size is 4 mm). Most infants who need respiratory support at birth are less than 30 weeks gestation and colonization of non-respiratory tissue (e.g. skin) would not generate aerosols during positive pressure ventilation (PPV). Therefore, it is our opinion at this time that it is highly improbable that a child at birth would generate infectious aerosol particles during PPV, even if born to a COVID-19 mother.

Given the low risk of vertical transmission and the low risk of aerosol exposure from neonatal resuscitation, Droplet/Contact precautions are suitable for the initial resuscitation of newborns, even those born to suspected or confirmed COVID-19 mothers.

This recommendation applies to neonatal resuscitation including PPV, intubation, and CPAP, based on principles of risk exposure in the newborn and the current restriction of N95 availability. This recommendation was made by majority agreement and not by unanimous decision. Therefore, we highly recommend continued surveillance of this practice with testing and continued clinical monitoring of newborns of suspected and confirmed COVID-19 positive mother. Should this surveillance lead to a different understanding of transmission risk, N95 masks could be provided to and worn by all health care providers in the resuscitation space (Health Ethics Alliance, 2020).
An exception to the above recommendation is if the resuscitation is performed in the OR where a maternal AGMP (e.g. intubation) has occurred for a mother who is suspected/confirmed COVID-19. Where facilities and human resources allow, we recommend the following:

- The baby should be removed from the OR, whether baby is well or requiring resuscitation, as soon as possible, in order to reduce the risk of the baby being infected by maternal aerosols.
- If baby is well, a health care provider (in clean PPE) should transfer the baby, in an incubator or open bassinet, to the newborn care environment (e.g. nursery, postpartum room).
- If the baby requires resuscitation, the provider from the OR should place the baby on warmer bed and other providers in droplet/contact PPE should begin resuscitation. After doffing the PPE from the OR and donning new PPE, the health care provider can assist in ongoing resuscitation and infant care.
- After resuscitation, the baby is transferred to the NICU or to the appropriate newborn care environment in a manner that is consistent with organization practice.
- The alternate care area requires cleaning according to PHO best practices after baby and team leave the room, regardless of what level of resuscitation was required.

If the infant does not require any respiratory support, placing them in an open bassinette is adequate for movement between hospital environments. Infants requiring CPAP or ventilation should be transferred in an incubator from the delivery environment to an ongoing care environment.

Appropriate follow-up care must be in place to ensure newborn screening and assessments (e.g. bilirubin check, and infant hearing screening) are performed at the correct time. Bathing the infant as soon as possible after birth is recommended in order to remove any virus that may have colonized on the surface of the infant skin. The exception to this would include infants where the bathing may cause instability in newborn thermoregulation. Separate mechanisms are required for follow-up of babies born to COVID-19 positive mothers such that they can safely return to a healthcare environment with appropriate PPE for health care providers.

This group recommends early discharge of well babies, after proper risk assessment has occurred.

Mother-Baby Dyad Care for Suspected/Confirmed COVID-19 Mothers

Given the risk of postnatal transmission, it is recommended that families with a suspected or confirmed COVID-19 mother are counseled regarding the risks and benefits of keeping mother and baby together vs separated and options discussed if possible and at the mother’s request. It is recognized that current national guidelines do not recommend separating babies from their mothers. Therefore, this task force supports either of following options:
A. **Baby stay in the mother’s room.** While caring for the baby in the mother’s postpartum room, there are several recommendations:

- Infant(s) should be 2 metres from the mother at all times unless she is providing direct care or breastfeeding.
- Mother must be placed in a private room or, if that is not possible, to be cared for in a room with no other patient.
- Mother should perform hand hygiene before all care and skin hygiene prior to breastfeeding.
- Mother should always wear a mask.
- Consideration should be given to caring for babies in incubators to provide an additional barrier.
- Wherever possible, there should be a barrier (such as a curtain or incubator) between mother and infant(s) to protect against droplets due to coughing.
- Infant(s) and mother can be discharged when well.
- Infant(s) should remain 2 metres from mother at home and these precautions should continue until the mother is proven negative according to current public health guidance.

B. **Separation of mother and baby.** In some sites, a separate newborn care area and care giver may be available for:

1. Women who are unable to care for their infants while in hospital due to significant symptoms; or
2. At the request of the mother or family to prevent post-natal transmission of COVID-19 to the baby.

While some institutions may be able to offer mother-baby dyad separation as part of their COVID-19 policy, it must be acknowledged that neighbouring institutions will have differing policies and transfer between institutions solely for that reason may not be practically accommodated.

Care provided to infants, where mother-baby dyad separation has occurred, should be done in accordance with infection control principles, including physical distancing where babies are cohorted in one room and appropriate PPE for all care providers (staff and family).

**Infant Testing**

Only infants born to confirmed COVID-19 mothers require testing for Sars-CoV-2.

**This panel recommends that infants born to mothers with confirmed COVID-19 at the time of birth should be tested for COVID-19 within 24 hours of delivery, regardless of symptoms.**

This collection should be done only after the newborn has been bathed and cleaned ensuring that any residual birth secretions in the nasal area have been removed. If an infant is swabbed within the first few hours of life, the face should be first cleansed to prevent contamination at the time of specimen collection. In the event that the newborn was not washed, the timing should be discussed with the most responsible provider. The recommended neonatal specimen is a nasopharyngeal swab (NPS) placed in universal
transport medium (UTM). Any symptomatic newborns should also be assessed for other causes of clinical disease according to the clinical findings.

If the maternal respiratory swab result is not yet available at 24 hours after birth and the mother and infant are ready for discharge and clinically well, arrangements for follow-up should be made such that the result can be communicated to the mother and the newborn can be swabbed if mother is COVID-19 positive. In these cases, swabs of newborn should be conducted as soon as possible after she is confirmed positive.

If maternal testing is pending at the time of mother-baby dyad discharge then follow-up must be ensured such that if maternal testing is positive the baby is tested in a timely manner. If bringing the baby back for testing is impractical, the baby should be tested prior to discharge.

Any positive COVID-19 test in a newborn should be repeated after discussion with a paediatric infectious disease consultant, who will assist with result interpretation (e.g. colonization vs infection) and may advise on further investigations. The decision for expanded testing would be made by the clinical team. Any symptomatic newborns should also be assessed for other causes of clinical disease according to the clinical findings.

Newborns may be discharged home while awaiting laboratory test results if clinically well and otherwise ready for discharge. Appropriate education to caregiver(s) should be provided about signs and symptoms of infection in the neonate, and when to seek care and advice.

**Babies Requiring Transfer to a Higher Level of Care of NICU/Special Care Nursery (SCN)**

Babies born to suspected or confirmed COVID-19 mothers who require transfer to a higher level of care should be cared for droplet-contact precautions and separated by at least 2 metres from the mother at all times. Ideally, the baby should be cared for in a separate room from the mother while awaiting transfer.

While it is not thought that the newborn at the time of birth is either infected with COVID-19 or capable of creating infectious aerosols, they may subsequently become infected from surface virus or exposure to virus during the process of birth. Additionally, prolonged care of a baby on respiratory support exposes care providers to longer duration of potential aerosols. While this risk is unknown, but felt to be low, out of an abundance of caution it is reasonable to transition to airborne precautions for babies requiring prolonged respiratory support (CPAP, high flow, ventilation).

There is no evidence to guide providers as to when this transition should occur. For hospitals with an NICU/SCN, it seems reasonable to change to airborne precautions when the baby is transferred to their room in the NICU/SCN. In the case of a hospital where a baby is being stabilized while awaiting transport to a higher level of care, it is reasonable for providers to change to airborne PPE after the initial resuscitation if the baby remains on respiratory support and is likely to remain at the institution for longer than 4-6 hours awaiting transport. Such a baby should be maintained in a single room with the door closed.
while awaiting the transport team. The neonatal transport team members will wear airborne PPE during their management of the baby and transport.

**Care and Testing of Babies in NICU/SCN**

As described above, while the newborn is very unlikely to generate infectious aerosols at birth, this may become possible later.

Therefore, RHPs providing care for babies requiring ongoing, potentially aerosolizing respiratory support in the NICU or SCN should use Airborne and Droplet/Contact precautions.

HFO/Jet/NIPPV/CPAP and the acts of intubation and extubating are all widely agreed to be AGMPs. Conventional ventilation of a patient with a cuffed ETT is generally not thought to be an AGMP, however, in the newborn ventilated with an uncuffed ETT it is unclear and as for pediatric and adult patients, this should be treated as an AGMP. Negative pressure rooms are preferred for babies on aerosolizing respiratory support, but, in the absence of such a room, a single patient room with the door closed can be used.

Mothers/caregivers who are COVID positive (or suspected if test result is not yet available) shall not enter the NICU/SCN until they are considered negative according to current MOH guidelines. This may include repeat testing of mother/caregiver to determine negative nasopharyngeal swab. All visitors/parents who are entering the NICU/SCN must have passed hospital screening protocol for COVID-19 symptoms or exposure.

Breastmilk feeding is encouraged as there is no current evidence of viral transmission in breastmilk. Mothers should express breastmilk with a designated manual or electric breast pump which should not be shared and must be patient specific. The mother should wash her hands before touching any pump or bottle parts, clean her breasts, put on gloves and a mask, and follow recommendations for proper pump cleaning after each use. The health care provider receiving bottles of EBM should wear gloves and wipe the bottles of EBM with a disinfectant antiviral wipe prior to transporting the EBM to the NICU/SCN. Where possible, EBM of suspected/confirmed Covid-19 positive mothers should be stored in a separate fridge from EBM or mothers who are not suspected/positive. The HCP collecting milk from the fridge should wear gloves to transport milk to patient room and where possible all milk preparation should be completed in the patient room.

In the NICU/SCN, babies who are not on potentially aerosolizing respiratory support or having other AGMPs may be cared for using droplet-contact precautions in single rooms or cohorted with other babies born to suspected/confirmed COVID-19 mothers. If babies are cohorted, they must be separated by 2
metres and/or in incubators with RHPs changing their droplet-contact PPE (possibly with the exception of their mask if institutions have policies about mask conservation) between babies.

If any visitor to NICU or RHP is determined to be a suspected or confirmed COVID case, the baby becomes a possible contact and should be isolated with appropriate additional precautions instituted. Hospital IPAC should be notified to institute proper follow-up. Any infant who is a post-natal contact of a confirmed COVID positive caregiver or RHP should remain isolated with appropriate additional precautions for 14 days according to MOH or local guidelines.

If the baby is on potentially aerosolizing respiratory support they should be placed in a negative pressure room or single room with door closed on airborne precautions. In the absence of potentially aerosolizing respiratory support, care in a single room or cohort on droplet-contact precautions is appropriate. Determining when the enhanced precautions can be discontinued for the infant will require local IPAC input as it will depend on the parent’s test results and symptoms. Testing may be required on the baby but this will again depend on individual circumstances and must be determined in consultation with IPAC.

If the mother is suspected for COVID-19 but her test result is not yet available, it is reasonable to continue enhanced precautions in the care of the infant and delay infant testing until the maternal result is known as infant testing is only required if the mother’s test is positive. Discontinuation of enhanced precautions for the infant should be done in consultation with local IPAC, but generally if the mother tests negative then the infant should not require ongoing enhanced precautions. If an infant tests positive, consultation with Pediatric Infectious Diseases is recommended.

NICU/SCN teams must adapt their rounding procedures to allow physical separation. Communication with parents outside rounds must be a priority if they are not allowed to join rounds. For parents who are excluded from the NICU/SCN, the health care teams must make use of electronic means to ensure that parents are fully updated on their infant’s condition.

Infants born to COVID-19 positive mothers should be tested within the first 24 hours of life and, if the initial test is negative, again at 48 hours of life, regardless of symptoms. Infants should be maintained on Droplet/Contact precautions with or without Airborne precautions as appropriate until results are reported.

- Infants who have a 24 or 48 hour COVID test positive should be discussed with a pediatric infectious disease specialist.
- Infants who have a negative test at 48 hours should be discussed with local IPAC to determine appropriate ongoing care measures.

Hospitals must consider what accommodations can be made for suspected/confirmed COVID-19 parents of infants who are moribund/undergoing end of life care and how they may be facilitated to be with their baby during that time.
Babies may remain in NICU/SCN care for weeks or months. Ontario testing guidelines must therefore allow for confirmed COVID-19 parents of NICU/SCN patients to be tested at the end of their illness to demonstrate that they have become negative and may safely enter the NICU/SCN to be with their baby.

**Breastfeeding Recommendations**

As there is no evidence of the presence of SARS-CoV-2 in breastmilk of infected women, breastfeeding is not contraindicated for mothers who are suspect or COVID-19 positive. Feeding choices should be made after discussion of the known and theoretical benefits and risks of breastfeeding and family choice should be supported.

In order to prevent transmission of SARS-CoV-2 from mother to infant, the following precautions should be adhered to for mothers who are confirmed or suspected COVID-19 patients:

- Mothers must hand wash before touching/reaching for their infant, bottles, breast pump, etc;
- Mothers must be masked while holding or feeding their infant;
- Mothers must cough or sneeze away from their infant while holding or feeding;
- Mothers must follow breast and skin cleansing hygiene before holding or feeding;
- Cleaning of pumps and bottles must adhere to institution’s Infection Protection and Control policies.

**Monitoring/Surveillance Recommendations**

The recommendation of mother-baby dyad on rooming in, breast feeding, and non-separation are based on the best evidence available at the writing of this guideline. We acknowledge that the global literature on this is limited to small numbers of cases and limited study design.

The task force feels it imperative that prospective surveillance of the mother-baby dyad be performed postpartum until 2 weeks to ensure the safety of this recommendation.

**Conclusion**

This guideline responds to the rapidly evolving range of international evidence on COVID-19 prevention, testing, treatment and surveillance of women and health care providers for potential transmission of infection. This interpretation is for Ontario maternal and newborn populations and publicly-funded services delivered at birth and shortly afterwards. The task force acknowledges that population health needs and access to maternal-newborn health services vary widely across Ontario. The ability for health care providers, health care environments and/or regions to comply with all aspects of this guideline may be influenced by circumstances outside of their control. This may include factors such as health human resources, system capacity, supply chain management of PPE resources, patient access and patient preferences. The task force and PCMCH committees will regularly review and recommend updates to the guideline to incorporate evidence-informed best practice tailored to the needs of individuals, sub-populations, birth environments, health care providers, regions and the province.
References


Sunnybrook Health Sciences. (2020, April 8). ALGORITHM FOR THE TRANSFER TO OR-B FOR PUI/COVID+ PATIENTS Decision for STAT (CRASH) CS under GA. ALGORITHM FOR THE TRANSFER TO OR-B FOR PUI/COVID+ PATIENTS Decision for STAT (CRASH) CS under GA. Toronto, Ontario, Canada: Sunnybrook Health Sciences.
